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ABBREVIATIONS
ERT Enzyme replacement therapy
NEPSY-II A Developmental
Neuropsychological
Assessment, Second Edition
WISC-III-
NL
Wechsler Intelligence Scales
for Children, Third Edition
(Dutch version)
AIM To examine the long-term consequences of glycogen storage in the central nervous
system (CNS) for classic infantile Pompe disease using enzyme replacement therapy.
METHOD Using neuropsychological tests and brain magnetic resonance imaging (MRI), we
prospectively assessed a cohort of 11 classic infantile Pompe patients aged up to 17 years.
RESULTS From approximately age 2 years onwards, brain MRI showed involvement of the
periventricular white matter and centrum semiovale. After 8 years of age, additional white-
matter abnormalities occurred in the corpus callosum, internal and external capsule, and
subcortical areas. From 11 years of age, white-matter abnormalities were also found in the
brainstem. Although there seemed to be a characteristic pattern of involvement over time,
there were considerable variations between patients, reflected by variations in
neuropsychological development. Cognitive development ranged from stable and normal to
declines that lead to intellectual disabilities.
INTERPRETATION As treatment enables patients with classic infantile Pompe disease to reach
adulthood, white-matter abnormalities are becoming increasingly evident, affecting the
neuropsychological development. Therefore, we advise follow-up programs are expanded to
capture CNS involvement in larger, international patient cohorts, to incorporate our findings
in the counselling of parents before the start of treatment, and to include the brain as an
additional target in the development of next-generation therapeutic strategies for classic
infantile Pompe disease.
Classic infantile Pompe disease is a progressive inheritable
myopathy caused by a deficiency of the lysosomal enzyme
alpha-glucosidase. This leads to an accumulation of glyco-
gen that mainly affects skeletal muscles and the heart. As
patients have severe mutations in the GAA gene, enzyme
activity is less than 1% in cultured fibroblasts. Characteris-
tically, they present before the age of 6 months with a
hypertrophic cardiomyopathy, progressive generalized
muscle weakness, and respiratory problems. Untreated
infants die before the age of 1 year.1 In 1999, the first
patients with classic infantile Pompe disease were treated
with recombinant human alpha-glucosidase. In 2006
enzyme replacement therapy (ERT) was registered.2 Over
the years, ERT has been demonstrated to significantly
improve survival, cardiac, and motor outcome.2–5 The first
surviving infants treated in our centre are now on the
threshold of adulthood.
A limitation of ERT is that it cannot pass the blood-
brain barrier. However, small amounts of glycogen are also
stored in the brain.6–12 Therefore, we looked at the poten-
tial consequences of glycogen storage in the central ner-
vous system (CNS) using neuropsychological tests and
brain magnetic resonance imaging (MRI) from the start of
therapy. Previously we found that intelligence ranged from
normal to mildly delayed. Early development was easily
underestimated if motor functioning was poor.5,13–15 Brain
MRIs showed predominantly periventricular white-matter
abnormalities.15 This was confirmed by a limited number
of other studies on relatively young patients.16–18
As no studies have related long-term neuropsychological
follow-up results to the brain abnormalities in patients up
to adulthood, we had two objectives: (1) to use brain MRI
and neuropsychological tests to study the long-term conse-
quences of glycogen storage on the CNS, and (2) to relate
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imaging results to our findings on neuropsychological
functioning in the oldest surviving patients.
METHOD
Patients
ERT with recombinant human alpha-glucosidase started in
1999 with a small group of patients. For the current fol-
low-up study, we included the 11 oldest classic infantile
patients of our current cohort (start of ERT between 1999
and 2009). Four initially received recombinant human
alpha-glucosidase from rabbit milk. Since 2003, all patients
were treated with ERT derived from Chinese hamster
ovary cells. The dose ranged from 20mg/kg every other
week to 40mg/kg/week. Inclusion criteria were: GAA activ-
ity of less than 1%; severe mutations in the GAA gene;
start of symptoms before 6 months; and hypertrophic car-
diomyopathy at diagnosis.
Study protocols were approved by the Institutional
Review Board. Written informed consent was obtained
from the children’s parents.
MRI
We performed MRI of the brain at least once per patient
using a 1.5T system, or a 3T system (EchoSpeed; GE
Healthcare, Milwaukee, WI, USA), and a dedicated
8-channel head coil. MRIs were scanned according to a
standardized protocol including T1-weighted, T2-
weighted, and fluid-attenuated inversion recovery images.
MRIs were scored by assessing white matter changes in
several anatomical regions, including (1) the supratentorial
region: frontal and occipital periventricular white matter,
the centrum semiovale, corpus callosum, external capsule,
posterior and anterior limb of the internal capsule; (2) sub-
cortical white matter, and U-fibres, and (3) the infratento-
rial region: decussation and cortical spinal tract at the
brain-stem level. We also assessed ventricle size (lateral
ventricles and fourth ventricles), and abnormal signal
intensity and/or volume loss of the nucleus dentatus, basal
nuclei, and thalami. All MRIs were rated by two indepen-
dent evaluators: a paediatric neuroradiologist (MHL), and
a paediatric neurologist (JMPvdH). If opinions diverged,
consensus was reached after deliberation.
Neuropsychological functioning
As early developmental tests in classic infantile Pompe
patients can be highly influenced by motor function-
ing,13,15 we focused on the neuropsychological test in
patients over the age of 5 years. Patients underwent regular
neuropsychological assessments. These were intended to
assess the following: (1) age 5 years: early development;
Griffiths Mental Developmental Scales (2) from 6 years
onwards: intelligence; the most recent Dutch version of
the Wechsler Intelligence Scales for Children, Third Edi-
tion (WISC-III-NL). The WISC-III-NL is divided into
two scales or into three factors. The scales are verbal intel-
ligence and performance intelligence. The factors are ver-
bal comprehension, performance organization, and
processing speed. For tetraplegic children, we used the
Raven Progressive Matrices.
In a subgroup of patients we tested memory (Rey Audi-
tory-Verbal Learning Test, Memory for Designs [A Devel-
opmental Neuropsychological Assessment, Second Edition
{NEPSY-II}]); language (Boston Naming Test, Compre-
hension of Instructions [NEPSY-II]); attention (Dot Can-
cellation Test, Inhibition [NEPSY-II]); executive
functioning (Verbal Fluency [NEPSY-II], Digit Span
[WISC-III-NL]); visual spatial functioning (Geometric
Puzzles [NEPSY-II], Design Copying [NEPSY-II], Rey
Complex Figure Test); processing speed (Processing Speed
Index [WISC-III-NL]); behaviour (Child Behavior Check-
list). All tests were administered in their most recent
normed and validated Dutch versions at time of assess-
ment. The children were assessed by two paediatric neu-
ropsychologists (FA, BE). Two patients were tested outside
our hospital, once each. One patient had an meticilline-
resistente Staphylococcus aureus infection and therefore
was tested in a home setting using the most recent Dutch
version of the Wechsler Nonverbal Scales. The other
patient was tested outside our hospital because of the initi-
ation of her therapy in Germany. She was tested there with
the most recent Dutch version of the Snijders Oomen non-
verbal intelligence test-revised 2½–7. As these two time-
points were important to determine development over
time, we decided to include these in the data set.
Patients’ test results were compared with the normative
data for the Dutch population. The mean score for the intel-
ligence tests is 100, with a standard deviation (SD) of 15
points. An IQ above 85 indicates normal development, a
score between 84 and 70 indicates mild developmental
delay, and a score below 70 indicates intellectual disability.
A disharmonic intelligence profile was defined according to
the appropriate table of the instruction manual (using the
95% confidence interval). A significant decline in IQ was
defined as a loss of more than 30 IQ points (>2 SD) or a
decline in raw scores, and a declining tendency as a loss of
more than 15 IQ points (>1 SD).19 For purposes of compar-
ison, all neuropsychological tests were converted into
z-scores. A neuropsychological test score of more than 1.5
SD below a child’s total IQ represents a weaker domain.19
RESULTS
Patients
Table I summarizes the patient characteristics. The current
age of the patients ranged from 7 years 7 months to
17 years 8 months. Motor outcome varied. Six of the 11
patients achieved the ability to walk, two of whom were
still able to do so at the last evaluation. Three patients had
minimal motor functioning and were respirator dependent.
What this paper adds
• In our long-term survivors treated intravenously with enzyme replacement
therapy, we found slowly progressive symmetric white-matter abnormalities.
• Cognitive development varied from stable and normal to declines towards
intellectual disabilities.
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Three patients died at the respective ages of 4 years
4 months, 4 years 5 months, and 15 years 7 months.
Brain MRI
In total, 21 brain MRIs were performed in 11 patients.
The patients’ ages at the time of MRI ranged from
7 months to 17 years 1 month. Five patients (age range
7mo–8y 6mo) had one MRI. Six patients (age range 2y
8mo–17y 1mo) had two to four MRIs. The interval
between the first and last MRI was 1 year 8 months to
8 years 9 months. Table II presents the scores of all brain
MRIs. At all ages, all patients had white-matter abnor-
malities in the centrum semiovale. Hyperintensities in the
frontal and occipital periventricular areas started to
appear at the age of 2 years 8 months. A tigroid hyperin-
tensity-pattern developed in the occipital region at various
ages.
After the age of 8 years 10 months (11 MRIs, five
patients), MRIs started to show additional white-matter
abnormalities in the subcortical areas, with sparing of the
U-fibres (all patients and all MRIs), and with involvement
of the external capsule (5/5 patients, 10/11 MRIs), of the
posterior limb of the internal capsule (4/5 patients, 8/11
MRIs), and of the corpus callosum (4/5 patients, 9/11
MRIs). In the corpus callosum, hyperintensities were first
observed in the splenium, and later in the genu and trun-
cus. Abnormalities in the basal ganglia were found in three
out of these five patients.
From the age of 11 years 4 months onwards (four
patients, six MRIs), hyperintensities were noticed in the
decussation (4/4 patients, 6/6 MRIs) and the corticospinal
tracts (4/4 patients, 5/6 MRIs). In addition, all patients had
widening of the lateral ventricles (4/4 patients, 6/6 MRIs).
The fourth ventricle was widened in only two patients (2/4
patients, 3/6 MRIs). To illustrate the progressive nature of
brain involvement in classical infantile Pompe disease, Fig-
ure 1 shows the sequential MRIs of the two patients with
the longest follow-up.
Intelligence
Table SI (online supporting information) presents the total
IQ scores and the scores on subscales of all patients from
the age of 5 years onwards. A total of 34 intelligence tests
were performed in nine patients. The age at the latest
assessment ranged from 6 years to 16 years 2 months. The
total intelligence scores over the period ranged from less
than 45 to 121.
Because of the various ages and varying degrees of
motor disability, it was not possible to test all patients with
the same instrument. Two tetraplegic patients were tested
with the Raven Progressive Matrices (patient 2 at ages 5y,
10y, and 13y; patient 4 at ages 12y and 14y). During fol-
low-up, development was stable in both; one had normal
intelligence and the other had mild developmental delay.
Two other patients (patients 8 and 11) were tested with
the Snijders Oomen Nonverbal Intelligence Test – Revised
and the Wechsler Nonverbal Scale of Ability (age 6y and
7y). Their total intelligence scores lay in the range of intel-
lectual disability.
Five patients (patients 1, 6, 7, 9, and 10) underwent mul-
tiple testing with the WISC-III-NL between the age of
5 years and 16 years. Figure 2 shows the total IQ, total
Table I: Patient characteristics
Patient
Age at
start of
ERT
(y:mo)
Current
age
(y:mo)
Invasive
ventilation
(age at onset,
y:mo) Mutations
CRIM
status
Last LVMI
Z-score<2
Hearing
aidsa
Impaired
visiona
Best motor
milestone
Last motor
function
1 0:4 17:5 – c.2481+102_2646+31del538
c.1799G>A
P Yes Yes Yes Walking Walking
2 0:7b 17:8 0:7 c.1115A>T
c.525delT
P Yes Yes Yes MMF MMF
3 0:2 4:4c 2:1 c.525delT
c.525delT
N No Yes No Sitting Sitting
4 0:8b 17:8 0:11 c.1913G>T
c.1548G>A
P No Yes Yes MMF MMF
5 0:2 4:5c 2:0 c.2741delinsCAG
c.2741delinsCAG
N Yes Yes No Walking Sitting
6 0:1 11:10 – c.del525T
c.1933G>T
P Yes Yes Yes Walking Sitting
7 16d 11:4 – c.2481+102_2646+31del538
c.2481+102_2646+31del538
P Yes Yes Yes Walking Walking
8 3d 9:0 2:8 c.1460T>C
c.1460T>C
P Yes No Yes Walking Sitting
9 0:2 8:7 – c.525delT
c.2481+102_2646+31del538
P Yes Yes Yes Standing Sitting
10 0:2 7:7 – c.2481+102_2646+31del538
c.2481+102_2646+31del538
P Yes Yes Yes Walking Sitting
11 0:2 15:7c 3:2 U U Yes Yes Yes Sitting MMF
All ages are stated in years and months (see also Ebbink et al.).15 aHearing and vision were sufficiently compensated at time of neuropsy-
chological testing. bPatients 2 and 4 started therapy in the end stage of the disease; both had minimal motor function, and became ventila-
tor dependent before the age of 1 year. cDeceased. ERT, enzyme replacement therapy; CRIM, cross-reactive immunological material; LVMI,
left ventricle mass index; P, positive; N, negative; MMF, minimal motor function; U, unknown.
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verbal IQ, total performance IQ, and processing-speed
index over time. The total IQ, total verbal IQ, and total
performance IQ of the two youngest patients remained
stable over time (patient 9 and 10); one patient had normal
development and the other had mild delay. The three
patients with the longest follow-up declined in their
IQ-scores. Patient 1 had a declining tendency in total IQ
and total verbal IQ from normal to mildly delayed. Patient
6 had a significant decline in total IQ and a declining ten-
dency on total verbal IQ and total performance IQ from
mildly delayed to intellectual disability. Patient 7 had a
declining tendency on total IQ and total performance IQ
from mildly delayed to intellectual disability. All five
patients declined significantly in their processing-speed
index. Patients 1, 7, and 10 had disharmonic profiles at the
age of 6 years (total verbal IQ>total performance IQ).
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k) (l)
Figure 1: Long-term magnetic resonance imaging follow-up in patients with classic infantile Pompe disease. (a) Axial T2-weighted image of a healthy
control patient aged 6 years. (b) Axial T2-weighted image of patient 1, aged 9 years. The asterisk indicates periventricular white-matter abnormalities.
(c) Axial T2-weighted image of patient 1, aged 17 years. The asterisk indicates additional involvement of the capsula externa, posterior limb of internal
capsule (PLIC), and corpus callosum. Note that the ventricles are also mildly widened. (d) Axial FLAIR (fluid-attenuated inversion recovery)-weighted
image of a healthy control patient, aged 6 years. (e) Axial FLAIR-weighted image of patient 4, aged 5 years. The asterisk indicates periventricular
white-matter abnormalities. (f) Axial FLAIR-weighted image of patient 4, aged 13 years. Asterisk shows the spread of white-matter abnormalities
towards the capsula externa. The PLIC is slightly involved as well. (g) Coronal T2-weighted image of a healthy control patient aged 9 years. (h) Coronal
FLAIR-weighted image of patient 1, aged 9 years, showing involvement of the periventricular white matter. (i) Coronal reformatted T2-weighted image of
patient 1, aged 17 years. Asterisk indicates spread towards the subcortical areas and corticospinal tracts. (j, k, l) Two transversal images and one coro-
nal FLAIR-weighted image of patient 4 at the ages of 5 years (j) and 13 years (k, l). Image (k) and (l) show involvement of the corticospinal tracts,
which is not seen on image (j).
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Patient 1 became harmonic after a decline in total verbal
IQ, and patients 7 and 10 remained disharmonic.
Follow-up MRI and IQ (patients 1, 6, 7, 9, 10)
To study the relationship between MRI and IQ, the IQs
of the patients assessed with the Griffiths and WISC-III-
NL were related to brain MRIs performed at similar ages
(time between MRI and IQ assessment <1y, range 0.5–
9mo). In patients with involvement of the centrum semio-
vale and periventricular white matter only, intelligence was
normal to mildly delayed (patients’ ages 2y 8mo–7y 6mo).
In those with additional white-matter abnormalities, the
total IQ scores indicated problems ranging from mild
developmental delay to intellectual disabilities (ages of
patients 9–17y). In these patients, a slight increase in
white-matter involvement co-occurred with a declining
tendency in their total IQ and total performance IQ (pa-
tient 7), total verbal IQ (patient 6), and processing-speed
index (patients 1, 6, and 7).
Additional neuropsychological domains
Additional neuropsychological evaluations were performed
in seven patients above the age of 5 years. Attention and
visual-spatial integration were tested in the five patients
who were able to perform the WISC-III-NL (patients 1,
6, 7, 9, and 10). All five patients had problems in their sus-
tained attention, but not in their selective attention.
Visual-spatial integration problems were found in three
patients (3/5).
Working memory, memory, language, and executive
functioning were tested in six patients. These tasks, most
of which were verbal, could also be performed in one fully
tetraplegic patient. Working memory was abnormal in five
patients (5/6). Two patients had memory problems (2/6).
No specific problems were found with regard to language
(0/6) or executive functioning (0/6). The Child Behavior
Checklist was administered to the parents of three patients.
Social problems were found in two patients. At the ages of
12 years (patient 1) and 5 years (patient 6) there were no
signs of behavioural problems on the Child Behavior
Checklist. At the ages of 16 years and 7 years, 4 years and
2 years later, mild affective and mild oppositional beha-
viour was reported in patient 1 and mild symptoms that
could be suggestive of attention-deficit–hyperactivity disor-
der were reported for patient 6. Mild social problems were
found in both patients.
DISCUSSION
With over 17 years of experience with ERT in patients
with classic infantile Pompe disease, insights in long-term
outcome are gradually expanding. As a result of ERT, sur-
vival and motor performance have improved significantly,
and cardiac hypertrophy has resolved in most patients.
One of the limitations of ERT is that it cannot cross the
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Figure 2: Intelligence-test scores of patients with classic infantile Pompe disease between the ages of 5 years and 16 years. ▲=Snijders Oomen
nonverbal intelligence test-revised 2½–7; ■=Griffiths Mental Developmental Scales; ●=Wechsler Intelligence Scales for Children, Third Edition (Dutch
version). aDecline in raw scores in processing-speed index; bFloor effect.
6 Developmental Medicine & Child Neurology 2018
blood-brain barrier. As time passes, our maturing patient
population shows that the disease is not only a muscle dis-
ease, but also affects the brain.
Brain
We noted a characteristic three-stage pattern of white-mat-
ter involvement that evolves from periventricular to sub-
cortical and from superior to inferior. For explicatory
reasons, we subdivided the process, which is likely to be
gradual, into three stages. In stage one (starting around 2y
of age), all the patients we evaluated had periventricular
white-matter involvement at the level of the centrum
semiovale. In stage two (from 8y of age onwards) the
white-matter abnormalities expanded to the subcortical
areas and internal and external capsule. In stage three
(from 11y of age onwards), infratentorial white-matter
areas also became involved.
Although there seemed to be a characteristic pattern of
involvement over time, the extent of the abnormalities, and
the rate of progression from stages one to three varied
between patients. For example, brain MRIs in five patients
aged between 8 years 6 months and 9 years 10 months
showed that some had more abnormalities than others at
the same age. Brain involvement appeared to be indepen-
dent of motor functioning. For example, one patient who
learned to walk within the normal age limits showed more
abnormalities on the MRI than a patient who became tet-
raplegic before the age of 1 year. Although white matter
changes were seen in the capsula interna, we did not note
spasticity as reported by Broomfield et al.20
On the basis of all of these findings we conclude that
the white-matter abnormalities on MRI in classic infantile
Pompe patients indicate a varied but slowly progressive
pattern of white-matter involvement.
This finding is new. To date, predominantly periventric-
ular white-matter abnormalities that were described are
consistent with our stage one.15–17,21 The lack of descrip-
tion of progression towards more extensive white-matter
involvement in earlier reports is explained by the absence
of reports on MRI in children after the age of 9 years,
which is when we observed progression towards stages two
and three.
Nonetheless, we note variations in the rate at which the
white-matter affliction progresses. These explain the three
cases reported (one by our own group) that indicate more
extensive white-matter disease at a relatively young age
(similar to stage two).22–24 Additionally, we found white-
matter abnormalities in the frontal regions on brain MRIs.
Theoretically this could lead to behavioural problems; this
is an important aspect for future studies to consider.
Neuropsychological profile
The variations in brain involvement are reflected by the
wide range of intelligence-test scores (i.e. from normal
intelligence to intellectual disabilities). This range is now
wider than in earlier studies. The development over time
varies from stable to neuropsychological decline. These
findings contrast with those of our previous study and of
four other studies on intelligence in classic infantile Pompe
disease, where cognitive development was stable, ranging
from normal to mildly delayed.13,15,16,25 Only one case
report on a 4-year-old patient and a recent case report on
a 9-year-old expressed concerns about ‘a not yet fully
described CNS phenotype’.23
Prompted by the potential effect of the disease on intel-
lectual performance shown by MRI, we performed addi-
tional neuropsychological tests, whose results showed a
consistent neuropsychological profile. Because of visuospa-
tial problems, patients appeared to be at risk of a dishar-
monic intelligence profile. All patients also had a lower
processing speed and problems in their sustained attention,
and several had problems with their working memory and
social interaction.
The question remains whether neuropsychological out-
come can theoretically be related to the white-matter
involvement we found in our Pompe patients. Firstly, the
white-matter abnormalities in our patients included the
frontal and parietal areas. A recent conceptual model
related intelligence to the interaction between the pre-
frontal and parietal cortex, which relies greatly on its
white-matter connectivity.26 This fronto-parietal integra-
tion network is believed to be involved not only in intelli-
gence but also in other neuropsychological functions, such
as attention, working memory, and processing speed.19 As
the white-matter abnormalities in our patients develop
within this network, it is conceivable that intelligence and
these specific neuropsychological functions are affected in
our patients.
A limitation of our study is that the group of patients
was relatively small, although it can be considered to be
large for a rare disease like classic infantile Pompe disease.
A strength of the study is that we included long-term fol-
low-up data from the four patients who were some of the
first to start ERT in 1999 (of whom three are still alive)
and from seven others that started ERT before 2009.
CONCLUSION
As our patient population with classic infantile Pompe dis-
ease matures into adulthood, knowledge of this initially
fatal muscle disease is broadening. It seems the brain is
now becoming the next puzzle in the treatment. We advise
expansion of follow-up programs to capture CNS/brain
involvement in larger, international patient cohorts, inclu-
sion of the current knowledge in the counselling of parents
before the start of treatment, and inclusion of the brain as
an additional target in the development of next-generation
therapeutic strategies for classic infantile Pompe disease.
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